



Centre for
Public Health

Merseyside Inter Agency Drug Misuse Database

January - March 2009

Wirral DAAT

Quarter 4 2008/09

**Lloyd Baron, Steven Griffith,
Martin Chandler, Jim McVeigh**

DRAFT REPORT

The final version will be available on the IAD website

www.cph.org.uk/iad

Acknowledgements:

The Authors would like to thank the following for their valuable contributions to the production of this report: Ellie McCoy and Paul Duffy.

We would also like to thank the data providers for their efforts in assisting and maintaining the monitoring process.

Contacts:

Martin Chandler
IAD Manager
Centre for Public Health
Faculty of Health & Applied Social Sciences
Liverpool John Moores University
Castle House
North Street
L3 2AY

(0151) 231 4531

m.chandler@ljmu.ac.uk

Lloyd Baron
IAD Researcher

(0151) 231 4521

L.R.Baron@ljmu.ac.uk

www.cph.org.uk/iad

Contents

	<u>Page</u>
Introduction	1
Arrest Referral	3
Table 1: Individuals assessed, by Gender and Age Group	
Table 2: Year to Date, by Gender and Age Group	
Table 3: Reported Main Drug(s) of Use, by Frequency of Use	
Syringe Exchange Services	5
Agency	
Table 4: Individuals by Gender	
Table 5: Individuals by Gender: Steroid Users omitted	
Table 6: Individuals by Age Group	
Table 7: Individuals by Age Group: Steroid Users omitted	
Table 8: Gender by Age Group of Individuals	
Table 9: Gender by Age Group: Steroid Users omitted	
Table 10: Year to Date, by Gender & Age Group	
Table 11: Year to Date, by Gender & Age Group: Steroid Users omitted	
Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender	
Table 13: Main Drug of Use for All Agency Syringe Exchange Clients, by Gender	
Table 14: Main Drug of Use, for New Agency Syringe Exchange Clients, by Age Group	
Pharmacy	11
Table 15: Individuals by Gender	
Table 16: Individuals by Age Group	
Table 17: Year to Date, by Gender & Age Group	
Combined	12
Table 18: Individuals in Syringe Exchange, by Gender	
Table 19: Individuals in Syringe Exchange, by Gender: Steroid Users omitted	
Table 20: Individuals in Syringe Exchange, by Age Group	
Table 21: Individuals in Syringe Exchange, by Age Group: Steroid Users omitted	
Table 22: Year to Date, by Gender & Age Group	
Table 23: Total Syringes Provided	

National Drug Treatment Monitoring System (NDTMS) 14

Table 24: Individuals in contact with Treatment Services, by Gender

Table 25: Year to Date, by Gender

Table 26: Individuals in contact with Treatment Services, by Age Group

Table 27: Year to Date, by Age Group

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Table 29: Individuals in contact with Treatment Services, by Main Drug of Use

Connexions 17

Table 30: Individuals in Contact with Connexions, by Gender

Table 31: Year to Date, by Gender

Table 32: Individuals in Contact with Connexions, by Age

Table 33: Year to Date, by Age

Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem

Table 35: Year to Date, by Drug/Alcohol Problem

Combined Datasets 19

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Table 37: Year to Date, by Gender & Age Group

Cross Matched Datasets 20

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets

Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.


To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle exchange schemes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

Year-to-Date figures will be provided for the current financial year, and will incorporate updated figures from previous quarters. The figures are calculated by aggregating successive quarterly datasets to omit double counting of those who present to services in each quarter. Year-to-Date data will be the most accurate reflection of annual service activity and will override previous quarterly data.



The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2008/09)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	157	82.6
Female	33	17.4
Age Group		
Under 18	0	0.0
18-19	15	7.9
20-24	30	15.8
25-29	34	17.9
30-34	33	17.4
35-39	35	18.4
40-44	21	11.1
45+	22	11.6
Total	190	100

Table 2: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	45	7.3	8	7.3	53	7.3
20-24	132	21.4	16	14.7	148	20.4
25-29	114	18.4	18	16.5	132	18.2
30-34	83	13.4	20	18.3	103	14.2
35-39	109	17.6	29	26.6	138	19.0
40-44	81	13.1	13	11.9	94	12.9
45+	54	8.7	5	4.6	59	8.1
Total	618	100	109	100	727	100

Table 3: Reported Main Drug(s) of Use, by Frequency of Use

Drug of Use	Daily	Weekly
Amphetamines	2	1
Benzodiazepines	5	2
Cannabis	41	9
Crack	21	26
Cocaine	8	24
Ecstasy	0	1
Heroin	45	33
Methadone	7	2
Other	1	1

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily or Weekly use of each drug. Where “Main drug” is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the “Main Drug”. However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

SYRINGE EXCHANGE SERVICES

Quarter 4 (2008/09)

Introduction

Data are collected directly from syringe exchange providers. Analysis of syringe exchange data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY SYRINGE EXCHANGE

Table 4: Individuals by Gender

New Clients	n	%
Male	139	94.6
Female	8	5.4
<i>Total</i>	147	100
All Clients		
Male	494	93.9
Female	32	6.1
<i>Total</i>	526	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	60	88.2
Female	8	11.8
<i>Total</i>	68	100
All Clients		
Male	218	87.6
Female	31	12.4
<i>Total</i>	249	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	2.0	4	<1
18-19	8	5.4	23	4.4
20-24	25	17.0	101	19.2
25-29	34	23.1	94	17.9
30-34	31	21.1	96	18.3
35-39	27	18.4	104	19.8
40-44	10	6.8	58	11.0
45+	9	6.1	46	8.7
Total	147	100	526	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	7	10.3	16	6.4
25-29	11	16.2	27	10.8
30-34	15	22.1	44	17.7
35-39	19	27.9	77	30.9
40-44	9	13.2	47	18.9
45+	7	10.3	38	15.3
Total	68	100	249	100

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	4	<1	0	0.0
18-19	23	4.7	0	0.0
20-24	99	20.0	2	6.3
25-29	91	18.4	3	9.4
30-34	88	17.8	8	25.0
35-39	93	18.8	11	34.4
40-44	52	10.5	6	18.8
45+	44	8.9	2	6.3
Total	494	100	32	100

Table 9: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	14	6.4	2	6.5
25-29	25	11.5	2	6.5
30-34	36	16.5	8	25.8
35-39	66	30.3	11	35.5
40-44	41	18.8	6	19.4
45+	36	16.5	2	6.5
Total	218	100	31	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	8	<1	1	1.4	9	<1
18-19	70	5.9	0	0.0	70	5.6
20-24	240	20.4	2	2.7	242	19.3
25-29	210	17.8	5	6.8	215	17.2
30-34	186	15.8	23	31.5	209	16.7
35-39	231	19.6	16	21.9	247	19.7
40-44	118	10.0	15	20.5	133	10.6
45+	115	9.8	11	15.1	126	10.1
Total	1,178	100	73	100	1,251	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	2	<1	0	0.0	2	<1
18-19	2	<1	0	0.0	2	<1
20-24	30	5.9	2	2.9	32	5.6
25-29	46	9.1	3	4.3	49	8.5
30-34	81	16.0	22	31.9	103	17.9
35-39	166	32.9	16	23.2	182	31.7
40-44	90	17.8	15	21.7	105	18.3
45+	88	17.4	11	15.9	99	17.2
Total	505	100	69	100	574	100

Table 12: Main Drug of Use for New Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	2	1.4	1	12.5
Crack	0	0.0	0	0.0
Heroin	45	32.4	7	87.5
Methadone	3	2.2	0	0.0
Melanotan	0	0.0	0	0.0
Steroids	79	56.8	0	0.0
Other	10	7.2	0	0.0
Total	139	100	8	100

Please Note: Due to changes in reporting methods we will now only report drug of use for new clients. Information on drug of use for all clients is available on request.

Table 13: Main Drug of Use for All Agency Syringe Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	6	1.2	1	3.1
Benzodiazepines	1	<1	0	0.0
Cocaine	7	1.4	2	6.3
Crack	0	0.0	0	0.0
Heroin	162	32.8	26	81.3
Methadone	17	3.4	2	6.3
Melanotan	0	0.0	0	0.0
Steroids	276	55.9	1	3.1
Other	25	5.1	0	0.0
Total*	494	100	32	100

***Please Note:** Totals may not be concurrent due to the reporting of Melanotan clients. Further details are available on request.

Table 14: Main Drug of Use for New Agency Syringe Exchange Clients, by Age Group

Age Group	Ampheta- mine		Benzodi- azepine		Cocaine		Crack		Heroin		Methadone		Steroids	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	-	-	-	-	0	0.0	-	-	0	0.0	0	0.0	3	3.8
18-19	-	-	-	-	0	0.0	-	-	0	0.0	0	0.0	8	10.1
20-24	-	-	-	-	0	0.0	-	-	5	9.6	0	0.0	18	22.8
25-29	-	-	-	-	1	33.3	-	-	7	13.5	0	0.0	23	29.1
30-34	-	-	-	-	1	33.3	-	-	11	21.2	2	66.7	16	20.3
35-39	-	-	-	-	0	0.0	-	-	16	30.8	0	0.0	8	10.1
40-44	-	-	-	-	0	0.0	-	-	8	15.4	0	0.0	1	1.3
45+	-	-	-	-	1	33.3	-	-	5	9.6	1	33.3	2	2.5
Total*	-	-	-	-	3	100	-	-	52	100	3	100	79	100

* % Totals are by Drug, not Age Group.

Please Note: Due to a change in reporting methods main drug of use by age group will only be reported for new clients. Information on age group for all clients is available on request.

PHARMACY SYRINGE EXCHANGE

Table 15: Individuals by Gender

New Clients	n	%
Male	40	76.9
Female	12	23.1
<i>Total</i>	52	100
All Clients		
Male	127	81.9
Female	28	18.1
<i>Total</i>	155	100

Table 16: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	3	1.9
18-19	0	0.0	3	1.9
20-24	5	9.6	9	5.8
25-29	13	25.0	20	12.9
30-34	17	32.7	33	21.3
35-39	9	17.3	38	24.5
40-44	7	13.5	30	19.4
45+	1	1.9	19	12.3
<i>Total</i>	52	100	155	100

Table 17: Year to Date, by Gender & Age Group

Age Group	Gender				<i>Total in Age Group</i>	
	Male		Female			
	n	%	n	%	n	%
Under 18	11	3.6	0	0.0	11	3.0
18-19	11	3.6	0	0.0	11	3.0
20-24	28	9.2	5	8.6	33	9.1
25-29	29	9.5	8	13.8	37	10.2
30-34	58	19.0	18	31.0	76	20.9
35-39	78	25.5	11	19.0	89	24.5
40-44	59	19.3	12	20.7	71	19.5
45+	32	10.5	4	6.9	36	9.9
<i>Total</i>	306	100	58	100	364	100

COMBINED PHARMACY AND AGENCY SYRINGE EXCHANGE

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 18: Individuals in Syringe Exchange, by Gender

New Clients	n	%
Male	163	90.6
Female	17	9.4
<i>Total</i>	180	100
All Clients		
Male	582	91.7
Female	53	8.3
<i>Total</i>	635	100

Table 19: Individuals in Syringe Exchange, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	84	83.2
Female	17	16.8
<i>Total</i>	101	100
All Clients		
Male	306	85.5
Female	52	14.5
<i>Total</i>	358	100

*Only known steroid users, based on Agency SES data, have been omitted.

Table 20: Individuals in Syringe Exchange, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	3	1.7	7	1.1
18-19	8	4.4	26	4.1
20-24	28	15.6	106	16.7
25-29	42	23.3	106	16.7
30-34	41	22.8	119	18.7
35-39	31	17.2	127	20.0
40-44	17	9.4	84	13.2
45+	10	5.6	60	9.4
<i>Total</i>	180	100	635	100

Table 21: Individuals in Syringe Exchange by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	3	< 1
18-19	0	0.0	3	< 1
20-24	10	9.9	21	5.9
25-29	19	18.8	39	10.9
30-34	25	24.8	67	18.7
35-39	23	22.8	100	27.9
40-44	16	15.8	73	20.4
45+	8	7.9	52	14.5
Total	101	100	358	100

Table 22: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	18	1.3	1	< 1	19	1.3
18-19	80	5.8	0	0.0	80	5.3
20-24	264	19.1	6	5.3	270	18.0
25-29	234	16.9	10	8.8	244	16.3
30-34	224	16.2	37	32.5	261	17.4
35-39	277	20.0	23	20.2	300	20.0
40-44	163	11.8	24	21.1	187	12.5
45+	125	9.0	13	11.4	138	9.2
Total	1,385	100	114	100	1,499	100

Table 23: Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	31,295	8,055	39,350	170,920

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

National Drug Treatment Monitoring System (NDTMS)

Quarter 4 (2008/09)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or in contact with treatment services, before this period.

Table 24: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	152	78.4
Female	42	21.6
<i>Total</i>	194	100
All Clients		
Male	2,037	73.2
Female	745	26.8
<i>Total</i>	2,782	100

Table 25: Year to Date, by Gender

New Clients	n	%
Male	705	78.4
Female	194	21.6
<i>Total</i>	899	100
All Clients		
Male	2,202	73.3
Female	803	26.7
<i>Total</i>	3,005	100

Table 26: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	16	8.2	123	4.4
18-19	6	3.1	84	3.0
20-24	9	4.6	295	10.6
25-29	23	11.9	487	17.5
30-34	40	20.6	547	19.7
35-39	53	27.3	638	22.9
40-44	27	13.9	383	13.8
45+	20	10.3	225	8.1
Total	194	100	2,782	100

Table 27: Year to Date, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	74	8.2	124	4.1
18-19	38	4.2	90	3.0
20-24	94	10.5	321	10.7
25-29	126	14.0	535	17.8
30-34	131	14.6	616	20.5
35-39	210	23.4	682	22.7
40-44	127	14.1	395	13.1
45+	99	11.0	242	8.1
Total	899	100	3,005	100

Table 28: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	188	96.9	2,743	98.6
White Irish	1	<1	13	<1
Other White	1	<1	2	<1
White & Black Caribbean	3	1.5	10	<1
White & Black African	0	0.0	1	<1
African	0	0.0	0	0.0
White & Asian	0	0.0	1	<1
Other Black	1	<1	4	<1
Caribbean	0	0.0	1	<1
Chinese	0	0.0	0	0.0
Other	0	0.0	7	<1
Unknown	0	0.0	0	0.0
Total	194	100	2,782	100

Table 29: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	110	56.7	1,881	67.6
Methadone	20	10.3	149	5.4
Other Opiates	1	<1	51	1.8
Benzodiazepine	1	<1	11	<1
Amphetamines	1	<1	46	1.7
Cocaine	25	12.9	297	10.7
Crack	5	2.6	107	3.8
Ecstasy	0	0.0	3	<1
Cannabis	30	15.5	208	7.5
Prescription Drugs	1	<1	15	<1
Other/Unknown	0	0.0	14	<1
Total	194	100	2,782	100

CONNEXIONS

Quarter 4 (2008/09)

Background

Connexions provide a support service for young people, aged 13-19. The Greater Merseyside Connexions Partnership provides data presented here.

Table 30: Individuals in Contact with Connexions, by Gender

Gender	n	%
Male	100	73.0
Female	37	27.0
Total	137	100

Table 31: Year to Date, by Gender

Gender	n	%
Male	147	68.7
Female	67	31.3
Total	214	100

Table 32: Individuals in Contact with Connexions, by Age

Age Group	n	%
16	28	20.4
17	41	29.9
18	39	28.5
19	29	21.2
Total	137	100

Table 33: Year to Date, by Age

Age Group	n	%
16	44	20.6
17	57	26.6
18	53	24.8
19	60	28.0
Total	214	100

Table 34: Individuals in Contact with Connexions by Drug/Alcohol Problem

Substance	n	%
Alcohol/Other*	52	38.0
Drugs	85	62.0
Total	137	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

Table 35: Year to Date, by Drug/Alcohol problem

Substance	n	%
Alcohol/Other*	82	38.3
Drugs	132	61.7
Total	214	100

*"Other" is generally used to refer to solvents although this is not necessarily always the case.

COMBINED DATASETS

Quarter 4 (2008/09)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, Syringe Exchange (Agency and Pharmacy), NDTMS and Connexions. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	2,618	76.2
Female	817	23.8
Age Group		
Under 18	182	5.3
18-19	184	5.4
20-24	417	12.1
25-29	594	17.3
30-34	641	18.7
35-39	717	20.9
40-44	427	12.4
45+	273	7.9
Total	3,435	100

Table 37: Year to Date, by Gender and Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	149	3.9	69	7.0	218	4.6
18-19	254	6.7	61	6.2	315	6.6
20-24	580	15.4	119	12.1	699	14.7
25-29	657	17.4	182	18.6	839	17.6
30-34	666	17.6	198	20.2	864	18.2
35-39	738	19.6	186	19.0	924	19.4
40-44	427	11.3	102	10.4	529	11.1
45+	303	8.0	64	6.5	367	7.7
Total	3,774	100	981	100	4,755	100

CROSS-MATCHED DATASETS

Quarter 4 (2008/09)

Data are shown for the crossover between each type of Syringe Exchange and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of Syringe Exchange site.

Fig 1: Crossover between Agency Syringe Exchange and NDTMS datasets




Fig 2: Crossover between Pharmacy Syringe Exchange and NDTMS datasets

